Glioblastoma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies Bayer, Chimerix, Aivita Biomedical

September 12 23:10 2023
DelveInsight Business Research LLP
DelveInsight’s “Glioblastoma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

DelveInsight’s “Glioblastoma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Glioblastoma Overview

Glioblastoma is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that innovative diagnostic strategies and new therapies have been developed. Glioblastoma is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced processes such as speech and emotions. The exact underlying cause of Glioblastoma is unknown. Some cases may develop from existing, low-grade astrocytomas (malignant transformation) or they may occur without any evidence of a previous tumor (de novo).

Glioblastoma Epidemiology Insights

  • The Total Diagnosed Incident Population of Glioblastoma in the 7MM comprised of 32,546 cases in 2021 and is projected to increase during the forecast period.

  • The Gender-specific Diagnosed Incidence of Glioblastoma in the United States, in which maximum cases were recorded in the male population i.e., 7,705 in 2021, as compared to the female population.

  • Among the EU-4, the UK countries, Germany accounted for the highest number of Glioblastoma cases, followed by France, whereas Spain accounted for the lowest number of cases in 2021.

  • In Japan, the Type-specific Diagnosed Incidence of Glioblastoma in Japan was of two types in which maximum cases were recorded of Primary Glioblastoma/ IDH-wild Type 2,541 in 2021 and is anticipated to rise during the forecast period.

Click here to learn more about the Glioblastoma Market Landscape

 The Report Covers the Glioblastoma  Epidemiology Segmented by:

  • Glioblastoma prevalent cases  

  • Glioblastoma incident cases 

  • Glioblastoma treatment cases 

  • Glioblastoma diagnosed cases 

Glioblastoma Market Outlook 

Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. The first step in treating glioblastoma is a surgical procedure to make a diagnosis, to relieve pressure on the brain, and remove as much tumor as possible safely. Glioblastoma surgery is performed to achieve a “maximum safe resection,” or remove as much of the tumor as possible without causing lasting neurological damage.

Key Companies Working in the Glioblastoma Market

  • Bayer

  • Chimerix

  • Aivita Biomedical

  • Denovo Biopharma

  • Northwest Therapeutics

And many others 

Glioblastoma Therapies Covered and Analyzed in the Report

  • Ofranergene obadenovec

  • Trans Sodium Crocetinate

  • Selinexor (KPT-330)

  • VBI-1901

And many others 

Learn more about the Key Companies and Emerging Therapies in the Glioblastoma Market

 

Table of Contents 

  1.  Key Insights 

  2.  Glioblastoma Introduction 

  3.  Executive Summary of Glioblastoma           

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  Glioblastoma  Emerging Therapies

  7.  Glioblastoma  Market Outlook

  8.  Market Access and Reimbursement of Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Appendix

  12.  Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

Learn about the detailed offerings of the report @ Glioblastoma Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services